ADMA at a glance
ADMA BIOLOGICS, INC. (ADMA, SEC CIK 1368514) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 16, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), ADMA BIOLOGICS, INC. (ADMA) reported revenue of $510.2 million (up 19.6% from FY2024) and net income of $146.9 million. Diluted EPS was $0.60.
- As of September 30, 2026, 31 institutional investment managers tracked by SignalX reported holding ADMA BIOLOGICS, INC. (ADMA) shares worth $1.0 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Grossman Adam S on November 16, 2026 of 15,000 shares at $13.72 per share.
- In the last 90 days, ADMA insiders reported 0 open-market purchases ($0) and 5 open-market sales ($2.2M) on Form 4, a net sale of $2.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $510.2M
- +19.6% vs prior year
- Insiders · 90 days
- 0 buys · 5 sells
- Net −$2.2M
- 13F holders
- 31 funds
- $1.0B · −1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business: End-to-end biopharmaceutical company manufacturing specialty biologics for immunodeficient and immune-compromised patients
- New emphasis on SG-001 for prevention/treatment of S. pneumoniae infections, with pilot batch completed and pre-IND planned in FY 2026
- Strategic shift: Divestiture of 3 plasma centers, moving to more flexible, capital-efficient plasma supply; 7 centers to remain operational post-divestiture
- Quantitative highlight: 20%+ production yield increase from FDA-approved yield enhancement process effective April 2025, first full year in FY 2026
- Noteworthy: Implementation of AI platform ADMAlytics started in 2024 to optimize plasma pooling and commercial operations, with ongoing expansion in 2025
Risk Factors
- FDA inspections risk: potential issuance of warning letters or enforcement actions due to non-compliance with cGMP at ADMA or third-party contractors
- Geopolitical exposure: supply chain disruptions and sales impact from Russia-Ukraine conflict and sanctions, plus risks in South America, Northern Africa, Middle East
- Supply chain vulnerability: reliance on third-party fill/finish contractors and plasma suppliers may delay finished drug product availability and commercialization
- Competitive risk: uncertain market acceptance and forecast inaccuracies for ASCENIV and plasma-derived products despite FDA approval and new manufacturing yield enhancements
- Financial risk: dependency on key customers accounting for significant revenue and risk of financial strain from need for additional equity/debt if profitability not maintained
Management Discussion & Analysis
- Revenue $510.2M in 2025, up 20% YoY from $426.5M, driven by ASCENIV ($362.5M, +51%), offset by BIVIGAM decline (-14%)
- Gross margin improved to 57.4% in 2025 vs 51.5% in 2024, due to favorable IG product mix and lower manufacturing costs
- Best segment ADMA BioManufacturing: $493.1M revenue (+19%), worst Plasma Collection Centers: $17.0M (+62%), but much smaller base
- Operating cash flow positive $118.7M in 2024, continued positive in 2025; $12.6M real estate acquisition; divestiture of 3 plasma centers for $12.0M in Dec 2025
- 2026 outlook: full year benefit of 20%+ yield enhancement process expected to drive margin expansion; FDA label expansion for ASCENIV anticipated H1 2026
AI summary of the ADMA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Risk Factors
- Newly added securities litigation risk: July 10, 2026 class action and consolidated derivative proceedings alleging Exchange Act violations
- Most materially updated competitive risk: new FDA-approved IVIG competitors since 2H 2025 using aggressive pricing, rebates and extended payment terms
- Regulatory risk: FDA inspections could trigger warning letters, recalls, supply disruptions or manufacturing restrictions for ADMA and suppliers
- Operational risk: high-titer RSV plasma meeting specifications represents less than 10% of tested donor samples
- Financial risk: $197.2 million JPMorgan debt outstanding, maturing August 5, 2028, with substantially all assets pledged as collateral
Management Discussion & Analysis
- Q3 revenue $141.1M, up 5.1% YoY from $134.2M
- Gross margin 70.8% vs 56.3% YoY, net income $49.9M vs $36.4M
- Best performer ASCENIV revenue $124.7M, up 30.7%; BIVIGAM worst, $15.4M, down 35.2%
- Cash $124.6M vs $87.6M at December 31, 2025; nine-month operating cash flow $105.2M vs $14.8M
- Competitive IVIG pricing pressured BIVIGAM; inflation and supply-chain costs expected through Q4 2026 and 2027
AI summary of the ADMA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- ADMA announced financial results for the three months ended September 30, 2026
- Business update accompanies the quarterly results
Item EX-99.1: Item EX-99.1
- Q3 revenue $141.1M, up 5% YoY, while ASCENIV revenue rose 31% to $124.7M
- GAAP net income $49.9M, up 37%, with basic EPS $0.22, up 47%
Item 2.02: Results of Operations and Financial Condition
- ADMA announced financial results for the three months ended June 30, 2026
- Business update included alongside quarterly results
Item EX-99.1: Item EX-99.1
- 2Q revenue $124.4M, up 2%; ASCENIV $102.9M, up 24%, offsetting BIVIGAM revenue decline to $19.4M
- Gross margin expanded to 69% from 55%, driven by ASCENIV mix and yield-enhanced manufacturing
Item 5.07: Submission of Matters to a Vote of Security Holders
- Two Class I directors elected through 2029: Alison C. Finger and Eduardo Rene Salas
- 199,267,547 shares represented, establishing quorum against 232,324,283 shares outstanding
AI summaries of ADMA 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ADMA
Don't miss the next ADMA filing
- Alerts as it files. A push when ADMA files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ADMA, by share count.
- Ask anything. An AI agent that reads every ADMA filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Grossman Adam S | M | Nov 16, 2026 | 15,000 | - |
| Guiheen Lawrence P. | M | Nov 16, 2026 | 10,000 | $5.00 |
| Grossman Adam S | Sell | Nov 16, 2026 | 15,000 | $13.72 |
| Grossman Adam S | Sell | Nov 16, 2026 | 6,000 | $13.72 |
| Grossman Adam S | M | Nov 16, 2026 | 15,000 | $5.40 |
| Guiheen Lawrence P. | M | Nov 16, 2026 | 10,000 | - |
| Guiheen Lawrence P. | Sell | Nov 16, 2026 | 10,000 | $13.92 |
| Grossman Adam S | Sell | Nov 5, 2026 | 42,000 | $12.00 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | $258.2M | $426.5M | $510.2M |
| Gross Profit | - | $219.6M | $292.8M |
| Operating Income | - | $139.0M | $191.4M |
| Net Income | - | $197.7M | $146.9M |
| Gross Margin | - | 51.5% | 57.4% |
| Op. Margin | - | 32.6% | 37.5% |
| Net Margin | - | 46.4% | 28.8% |
| Balance Sheet | |||
| Total Assets | - | $488.7M | $624.2M |
| Equity | - | $349.0M | $477.3M |
| ROE | - | 56.6% | 30.8% |
| Per Share | |||
| EPS | - | $0.81 | $0.60 |
| Cash Flow | |||
| Operating CF | - | $118.7M | $50.4M |
| CapEx | $4.8M | $8.2M | $22.6M |
Source: XBRL data in ADMA BIOLOGICS, INC. (ADMA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate ADMA share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 31 | $1.04B |
| Q2 2026 | 32 | $913.0M |
| Q1 2026 | 33 | $1.03B |
| Q4 2025 | 30 | $1.98B |
| Q3 2025 | 30 | $1.76B |
| Q2 2025 | 29 | $2.14B |
| Q1 2025 | 28 | $1.55B |
| Q4 2024 | 24 | $1.24B |
- Bridgewater Associates LP+574.6K (+143%)
- Millennium Management+562.2K (+49%)
- JPMorgan Chase & Co+524.6K (+190%)
- AQR Capital Management+518.8K (+34%)
- Principal Financial Group+498.0K (+36%)
- State Street Corp−3.44M (-20%)
- BlackRock−1.05M (-3%)
- Citadel Advisors LLC−900.4K (-66%)
- Vanguard Portfolio Management LLC−881.3K (-9%)
- Goldman Sachs Group−696.4K (-20%)
- FMR LLC (Fidelity)−389.5K
Source: 13F-HR filings on SEC EDGAR (aggregated from 237 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ADMA filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 16, 2026 | - | - | - |
| 4 | Nov 5, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| SC 13G | Aug 7, 2026 | - | - | |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 28, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 8-K | Jun 2, 2026 | - | Analysis | |
| 4 | May 28, 2026 | - | - | |
| 4 | May 12, 2026 | - | - | |
| 10-Q | May 6, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 6, 2026 | - | Analysis | |
| 8-K | May 4, 2026 | - | Analysis | - |
| SC 13G | Apr 29, 2026 | - | - | |
| 4 | Apr 3, 2026 | - | - | - |
| 8-K | Mar 27, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 17, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 10, 2026 | - | - | - |
| 4 | Mar 9, 2026 | - | - | - |
| 8-K | Mar 2, 2026 | - | Analysis | - |
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ACLX · Arcellx, Inc.Biological Products, (No Diagnostic Substances)
ADMA SEC filings: frequently asked questions
Are ADMA insiders buying or selling?
In the last 90 days, ADMA BIOLOGICS, INC. (ADMA) officers, directors and 10% owners reported no open-market purchases and 5 open-market sales worth $2.2 million by 2 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ADMA stock?
As of September 30, 2026, the largest ADMA BIOLOGICS, INC. (ADMA) holders among the 13F filers tracked by SignalX were BlackRock ($374.2 million), State Street Corp ($137.2 million), Vanguard Capital Management LLC ($95.0 million), Vanguard Portfolio Management LLC ($92.3 million), D.E. Shaw & Co ($56.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ADMA's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), ADMA BIOLOGICS, INC. (ADMA) reported revenue of $510.2 million (up 19.6% from FY2024) and net income of $146.9 million. Diluted EPS was $0.60. The figures come from the XBRL data in the 10-K.
What are the main risks in ADMA's latest 10-K?
In the 10-K filed February 25, 2026, ADMA BIOLOGICS, INC. (ADMA) flagged: FDA inspections risk: potential issuance of warning letters or enforcement actions due to non-compliance with cGMP at ADMA or third-party contractors. Geopolitical exposure: supply chain disruptions and sales impact from Russia-Ukraine conflict and sanctions, plus risks in South America, Northern Africa, Middle East. (AI summary of the Risk Factors section.)
What did ADMA report in its latest 8-K?
ADMA BIOLOGICS, INC. (ADMA) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). ADMA announced financial results for the three months ended September 30, 2026.
What are the latest ADMA SEC filings?
ADMA BIOLOGICS, INC. (ADMA) filed its latest 10-K annual report on February 25, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 16, 2026.
What is ADMA's SEC CIK number?
ADMA BIOLOGICS, INC. (ADMA)'s SEC Central Index Key (CIK) is 1368514. EDGAR lists every ADMA filing under that number.
Ask anything about ADMA
The research agent reads ADMA's filings, financials, insider trades and 13F holders, then answers with sources.